Breaking News

Study says FDA allowed risky tests of blood substitutes / hospitals participating in the study could give the blood substitute to patients without their knowledge

0 0

Public release date: 29-Apr-2008

CHICAGO | Experimental blood substitutes raised the risk of heart attack and death, yet U.S. regulators allowed human testing to continue despite warning signs, a scathing new report says.

The U.S. Food and Drug Administration fell short, the report contends, even as red flags popped up during studies by five biotech companies. Rules barred the FDA from releasing company trade secrets, and that kept some information hidden and may have led to unnecessary heart attacks and deaths, wrote the authors, who are government scientists and consumer advocates.

“There shouldn’t be secret science,” said the lead author of the report, Charles Natanson of the National Institutes of Health Clinical Center. Safety data need “to be made public expeditiously so science can build on the mistakes” of previous research, he said.

The report, being published online today by the Journal of the American Medical Association, is the latest analysis of the risks of blood substitutes, which have been in testing for more than a decade. It was written by scientists with the NIH Clinical Center and advocates with the watchdog group Public Citizen.

One of the biotech companies, Evanston, Ill.-based Northfield Laboratories Inc., conducted a national study in 2005-06 involving 720 patients through 32 trauma centers, including the University of Kansas Medical Center.

KU Medical Center stocked ambulances in Wyandotte, Douglas and Leavenworth counties with Northfield’s blood substitute, PolyHeme. The study ended in August 2006.

The hospitals participating in the study could give the blood substitute to patients without their knowledge, so KU Medical Center gave blue wristbands to residents who requested them that would show they did not want to receive PolyHeme.

Johnson County officials opted out of the study, saying they did not want to participate because of the lack of consent by unconscious trauma patients.

A safe replacement for blood would be a breakthrough for medicine and a big money-maker for companies that produce it. It could save lives on battlefields. Unlike ordinary blood, it could, theoretically, be stored for years without refrigeration. It also would work with any blood type and would not carry infections like hepatitis or the AIDS virus.

By the end of 2000, a dozen studies of blood substitutes had been completed. By then, FDA officials would have known enough about cumulative risks to put a halt on further experiments, the JAMA report contends.

But the FDA looked at each product and each use separately — in surgery, in trauma, in stroke patients — rather than pooling the results to get a fuller picture of the risk, Natanson said.

In 2006, after a lawsuit by Public Citizen protesting a closed-door hearing, the FDA halted a test by the Navy, which planned to use a blood substitute on civilian trauma victims. Such tests raised ethical concerns about giving trauma patients an experimental product without their consent.

Jay Epstein, director of FDA’s office of blood research and review, defended the agency’s decisions about human testing of the products despite risks. The agency has found enough differences among the individual products and their intended uses to allow some studies to proceed, Epstein said Friday in a conference call with reporters.

Currently, there are no approved blood substitutes or clinical studies of them in the United States. However, American companies are testing them on people in South Africa and seven European countries. South Africa has approved one of the products, Hemopure, made by Biopure Corp., based in Cambridge, Mass., for use in anemic surgery patients.

Ralph’s Note – Experimenting on people without consent, with a drug that is dangerous. With the approval of a government agency. My solution to this, is that the FDA official responsible for this should volunteer for a blood transfusion with this new product.

About Post Author

Ralph Turchiano

I have a strong affinity for the sciences which led me to create my sites. My compulsion for the past decade has been reviewing literally every peer-reviewed research article. Which can easily be validated by following my posts. To me, science is where the real news is, as it will mold our destiny beyond that of politics or economics. 😉 Please feel free to e-mail: 161803p314159@gmail.com
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleppy
Sleppy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
%d bloggers like this: